United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing Market Report and Forecast 2026-2035

United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing Market Overview

The United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing market reached a value of approximately USD 5.26 Billion in 2025. The market is witnessing steady growth, driven by the rising prevalence of endocrine disorders, increasing demand for accurate hormone diagnostics, and widespread adoption of automated immunoassay platforms across clinical laboratories. Continuous technological advancements in CLIA analyzers, expanding test menus for thyroid, reproductive, adrenal, and metabolic hormone assessment, and growing emphasis on early disease detection are further supporting market expansion. In addition, increasing healthcare expenditure, improved laboratory infrastructure, and favorable regulatory approvals for innovative diagnostic assays are encouraging broader adoption of CLIA endocrine testing solutions across hospitals, diagnostic laboratories, specialty endocrinology clinics, and research institutions.

United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing Market Growth Analysis and Key Influencers

United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing Market Dynamics

This section analyzes factors influencing the market, including growth drivers, market restraints, emerging opportunities, technological advancements, product innovations, regulatory developments, laboratory automation trends, and evolving diagnostic practices across endocrine testing.

United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing Market Growth Drivers

FDA Testosterone Clearance Supports US CLIA Endocrine Testing Market Growth

Rising demand for automated hormone testing and faster endocrine disorder diagnosis is supporting market growth in the United States. For instance, in May 2026, Revvity received FDA clearance for its Total Testosterone automated chemiluminescence immunoassay through Immunodiagnostic Systems, adding to its cleared free testosterone and SHBG tests. This approval is expected to improve workflow efficiency, support broader testosterone-related disorder testing, and increase adoption of automated CLIA endocrine assays during the forecast period.

United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing Market Restraints

Extended FDA Review Restrains US CLIA Endocrine Testing Market Development

Strict validation needs and longer regulatory review timelines remain key market restraints for CLIA endocrine testing products in the United States. For instance, in February 2026, Siemens Healthcare Diagnostics received FDA 510(k) clearance for Atellica IM TSH3-Ultra II after a 262-day review cycle. The assay is used for quantitative thyroid-stimulating hormone testing in serum and plasma. Such timelines may slow product launches, increase documentation burden, and delay wider test-menu expansion for laboratories.

United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing Market Opportunities

Growing Demand for Reproductive Hormone Testing to Boost the Market Expansion

Increasing fertility care demand and rising use of automated reproductive hormone panels are creating market opportunities in the United States. For instance, in June 2026, Roche Diagnostics listed Elecsys Estradiol III in commercial distribution, with the device identified as a chemiluminescent immunoassay kit for quantitative estradiol hormone measurement. This development is expected to support broader reproductive endocrinology testing, improve lab menu depth, and strengthen demand for automated endocrine assay platforms during the forecast period.

United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing Market Trends

Laboratory Automation Platforms Shape US CLIA Endocrine Testing Market

Laboratories are prioritizing higher throughput and reduced manual handling, shaping market trends in CLIA endocrine testing. For instance, in May 2025, Revvity’s EUROIMMUN launched the IDS i20 automated random-access platform for chemiluminescence immunoassays, supporting endocrinology and other specialty testing areas. The platform can process multiple analytes on one instrument and support higher test throughput. This shift is expected to drive demand for automated endocrine testing systems across clinical laboratories during the forecast period.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing Market Share

Blood/Serum Samples Likely to Dominate the Market Segment by Sample Type

Blood/serum samples are likely to dominate the sample type segment, as they held approximately 76% market share in the historical period and are expected to maintain their strong position throughout the forecast period. Their widespread use in routine endocrine diagnostics, compatibility with automated CLIA platforms, and ability to deliver consistent analytical performance continue to support laboratory preference. Increasing demand for high-throughput hormone testing further reinforces the importance of blood/serum samples within the market.

Leading Players in the United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing Market

United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing Market Segmentation

Key Questions Answered in the United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing Market Report

• What was the United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing market value in 2025?
• What is the United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing market forecast outlook for 2026-2035?
• What major factors aid the demand for the United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing market trends?
• Which test type segment is expected to dominate the market?
• Which product segment is expected to hold the largest market share?
• Which sample type is expected to account for the highest market share?
• Which application is expected to account for the highest market share?
• Which end user is expected to account for the highest market share?
• Who are the key players in the United States Chemiluminescence Immunoassay (CLIA) Endocrine Testing market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: Interviews with IVD manufacturers, CLIA platform providers, endocrinologists, lab directors, regulatory specialists, distributors, and experts in endocrine testing.
• Secondary Research: FDA databases, CMS guidance, company releases, assay documents, journals, endocrinology guidelines, patents, investor materials, and peer-reviewed diagnostic literature.
• Validation: All quantitative estimates are triangulated using top-down and bottom-up market modeling, validated through expert feedback loops.